Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | GJB2 | P29033 | 4/20 | 0.50 |
| ▸ | GBA1 | P04062 | 2/20 | 0.49 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.45 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27710626 | 1.00 | MAPK1 (0.59) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| SCHEMBL28061284 | 1.00 | MAPK1 (0.59) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| SCHEMBL8614698 | 1.00 | MAPK1 (0.59) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| SCHEMBL17640864 | 0.98 | MAPK1 (0.61) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| SCHEMBL16250422 | 0.98 | MAPK1 (0.61) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| SCHEMBL28995607 | 0.98 | MAPK1 (0.61) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| SCHEMBL28364147 | 0.98 | MAPK1 (0.61) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| SCHEMBL28264760 | 0.98 | MAPK1 (0.61) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| Hydrochloric Acid SCHEMBL9403705 | 0.97 | MAPK1 (0.60) | MAPK1GJB2GBA1LGALS8LGALS3 | |
| Hydrochloric Acid SCHEMBL9403706 | 0.97 | MAPK1 (0.60) | MAPK1GJB2GBA1LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110023321-A | Polynucleotide constructs | 索尔斯蒂斯生物有限公司 | 2019-07-16 | — | — | CN | claimed |
| CN-107109405-A | Polynucleotide constructs with Bioreversible and abiotic invertibity group | 索尔斯蒂斯生物有限公司 | 2017-08-29 | — | — | CN | claimed |
| CN-106072660-A | A kind of micropill loading nanometer selenium and preparation method thereof | 国家海洋局第三海洋研究所 | 2016-11-09 | — | — | CN | claimed |
| CN-105814205-B | Complement component iRNA composition and its application method | 阿尔尼拉姆医药品有限公司 | 2019-11-19 | — | — | CN | disclosed |
| CN-110462031-A | Retargeting viruses or VLPs | DEUTSCHES PRIMATENZENTRUM GMBH DPZ LEIBNIZ INST FUR PRIMATENFORSCHUNG | 2019-11-15 | — | — | CN | disclosed |
| CN-110295167-A | SERPINC1 iRNA composition and its application method | 基酶有限公司 | 2019-10-01 | — | — | CN | disclosed |
| CN-110272901-A | SERPINC1 iRNA composition and its application method | 基酶有限公司 | 2019-09-24 | — | — | CN | disclosed |
| CN-110249053-A | COMBINATION THERAPY FOR C3 INHIBITION | 阿佩利斯制药有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-110227154-A | Anti-angiogenic therapy for the treatment of ovarian cancer | 霍夫曼-拉罗奇有限公司 | 2019-09-13 | — | — | CN | disclosed |
| CN-110229198-A | A kind of preparation method of pharmaceutical intermediate that treating hepatitis | 南京博源医药科技有限公司 | 2019-09-13 | — | — | CN | disclosed |
| CN-110139655-A | Compounds and methods for diagnosing and treating viral infections | 纳维迪亚生物制药有限公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-106589132-A | Compositions and methods for producing a composition | 布里斯托尔-迈尔斯斯奎布公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-101796063-B | methods of treatment using glycopegylated G-CSF | 拉蒂奥法姆有限责任公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-106470688-A | Oligomers and oligomer conjugates | 豪夫迈·罗氏有限公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106456743-A | Glycotargeting therapeutics | 洛桑聚合联合学院 | 2017-02-22 | — | — | CN | disclosed |
| CN-106232624-A | Complement factor Bb antibodies | 阿勒根公司 | 2016-12-14 | — | — | CN | disclosed |
| CN-106075435-A | For the method treating multiple sclerosis | 健泰科生物技术公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-106061466-A | Leptin mRNA compositions and formulations | 诺华股份有限公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-105982912-A | Pharmaceutical composition containing sodium hyaluronate and chondroitin sulfate | 黄绣川 | 2016-10-05 | — | — | CN | disclosed |
| CN-103554263-B | Apoptotic anti-IgE antibodies in conjunction with the IgE that film combines | 健泰科生物技术公司 | 2016-09-28 | — | — | CN | disclosed |